Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ministry of Health and Welfare outlined detailed provisions to implement a new "anti-rebate law," which will enable courts to punish both contributors and receivers of rebates. Passed overwhelmingly by South Korea's National Assembly on April 28, the law goes into effect Nov. 28, and will be enforced by the ministry.Under the new regulations, pharmas will be able to offer "sample" drugs as long as they are offered the "minimum packing unit," said the ministry, adding that they will also be able to offer minimal amounts of drugs and research fees to those conducting clinical trials

You may also be interested in...



Korea’s Health Ministry Tightens Grip On Healthcare Professionals And Companies For Illegal Marketing

Draft regulation would increase license suspensions for healthcare professionals, and puts companies at greater risk of losing sales licenses and entire distribution offices.

Korean Government Task Force Uncovers Illegal Rebates From Device Firms

With the help of state prosecutors, Korea’s health ministry expands the scope of anti-rebate surveillance to the medical device sector.

Korea Continues Crackdown On Pharma Kickbacks; First Doctor Sentenced To Jail

After a year on the books, Korea’s new anti-rebate law nabs its first healthcare professional.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel